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Original Article
The PACE study: Past-year prevalence
of migraine in Parma’s adult general
population
Tullia Ferrante1, Paola Castellini1, Giorgia Abrignani1,
Lilia Latte1, Marco Russo1, Cecilia Camarda2, Licia Veronesi1,
Cesira Pasquarella1, Gian Camillo Manzoni1 and Paola Torelli1
Abstract
Background: In the literature there are few data about the prevalence of primary headaches, including migraine, in the
Italian general population. The PACE study (PArma CEfalea, or ‘Headache in Parma’) is an observational study aimed at
detecting the prevalence and clinical features of primary headaches in the city of Parma’s adult general population.
Materials and methods: A total of 904 subjects representative of Parma’s adult general population were interviewed face-
to-face by a physician from the Parma Headache Centre. They were given a specially designed and validated questionnaire
for the diagnosis of primary headaches according to the ICHD-II criteria.
Results: Past-year adjusted prevalence of definite migraine, including migraine with and without aura and chronic migraine,
was 24.7% (95% CI 21.9 to 27.5); 13% (95% CI 9.7 to 16.4) were men and 32.9% (95% CI 28.8 to 37.0) were women.
Past-year prevalence of probable migraine was 5.1% (95% CI 3.6 to 6.5): 5.2% (95% CI 3.0 to 7.4) in men and 5% (95% CI
3.1 to 6.9) in women.
Conclusions: The high prevalence of definite migraine is the major difference between our results and the literature data.
Such a difference in results may be due to the use of a different investigational approach compared with the other
epidemiological studies. However, an actual higher frequency of migraine in the Italian general population cannot be
excluded given the lack of studies on this topic.
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Introduction
Primary headaches represent a major problem for
public health systems because they are widely distrib-
uted throughout the world, have a high prevalence, and
aﬀect people in all age groups. Many studies have been
conducted in various countries, mostly in North
America and Western Europe (1), to determine the
prevalence of primary headaches.
In Italy, the prevalence and features of primary
headaches in the general population have been little
studied to date. There are few Italian studies, and
they present at least one of the following limitations:
they either concern only a segment of the adult general
population, notably people in the most advanced age
groups (2–4), or apply the diagnostic criteria set by the
Ad Hoc Committee on Classiﬁcation of Headache in
1962 (5,6) or by the International Headache Society
(IHS) in 1988 (2,3,7) and therefore preceded publica-
tion of the International Classiﬁcation of Headache
Disorders, second edition (ICHD-II) in 2004 (8). We
deemed it useful to conduct an observational study,
called PACE (PArma CEfalea, or ‘Headache in
Parma’), aimed at detecting the prevalence and clinical
features of primary headaches in the city of Parma’s
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adult general population. In this article we report data
about the prevalence of migraine, including probable
migraine. Additional data will be presented in future
articles.
Materials and methods
Our survey was conducted between September 2007
and February 2009 in Parma, a city in the Emilia-
Romagna region of northern Italy. As of 31
December 2006 (Table 1) the city had 152,140 inhabi-
tants aged 18 years or over (71,280 men, 80,860
women). The oﬃcial census of Parma residents as of
31 December 2006 was provided by the Parma
Municipal Statistics Oﬃce (9).
Sampling
Our initial study sample consisted of all residents reg-
istered with a GP in downtown Parma. Electronic
patient records for each GP practice (as of 1 January
2007) were oﬃcially provided by the Parma local
healthcare agency of Italy’s National Health Service
(NHS).
Our study population can be considered representa-
tive of the Italian adult general population, because in
Italy primary care must be provided by a physician free
of charge to each citizen from birth. The maximum
number of patients per GP is 1500, but if the GP so
requests, this number can be reduced to less than 1500.
Italy’s NHS keeps oﬃcial records with names and per-
sonal data of patients in the practice of each primary
care provider. Trust is crucial in the relationship
between patients and their family doctors. For primary
care providers to best fulﬁl their role, patients must be
free to make their choice with no geographic, adminis-
trative or economic constraints. Every citizen may then
decide at any time to change their primary care pro-
vider by simply addressing a request to the local NHS
healthcare agency. The GP’s direct involvement was
crucial to our study design. Our choice of the initial
study sample was inﬂuenced by the number of patients
in his practice (n¼ 1300), as well as by the successful
results of past cooperation between our team and the
GP (10). The GP did not receive any economic incen-
tive to participate in the study. We removed from the
GP’s patient list all subjects aged below 18 years.
Our initial study sample consisted of 1270 subjects,
681 women and 589 men.
The study participants were recruited by the GP,
who presented them with an overview of the study
and arranged for an appointment to interview them
at his oﬃce or at our Headache Centre. Those who
were interested in participating in the study, but said
they were unable to reach the appointment venue, were
interviewed by phone.
Interview and case definition
The interview was conducted face-to-face by one of the
physicians from the Parma Headache Centre and con-
sisted of the administration of a specially designed
13-section questionnaire for the diagnosis of primary
headaches in the general population (11), followed by
a neurological examination. The questionnaire included
a screening question: ‘Have you had a headache in the
last year?’ to detect subjects with past-year headache.
Through questions in the section about aura and head-
ache, it was possible to diagnose the primary headache
types that each subject was suﬀering from.
Table 1. Gender and age distribution of Parma’s general population, of the initial sample and of responders
Age (years)
Parma’s general populationa Initial sampleb Respondersc
F M Total F M Total F M Total
n % n % n % n % n % n % n % n % n %
18–29 10253 12.7 10582 14.9 20835 13.7 82 12.1 69 11.7 151 11.9 51 10.0 33 8.3 84 9.3
30–39 15105 18.7 15208 21.3 30313 19.9 86 12.6 93 15.8 179 14.1 55 10.8 51 12.9 106 11.7
40–49 13834 17.1 13845 19.4 27679 18.2 98 14.4 104 17.7 202 15.9 78 15.4 61 15.4 139 15.4
50–59 11738 14.5 10628 14.9 22366 14.7 106 15.6 98 16.6 204 16.1 96 18.9 74 18.7 170 18.8
60–69 11505 14.2 9925 13.9 21430 14.1 103 15.1 103 17.5 206 16.2 86 16.9 88 22.2 174 19.2
70–79 10059 12.4 7239 10.2 17298 11.4 107 15.7 81 13.8 188 14.8 93 18.3 64 16.2 157 17.4
>79 8366 10.4 3853 5.4 12219 8.0 99 14.5 41 6.9 140 11 49 9.6 25 6.3 74 8.2
Total 80860 53.1 71280 46.9 152140 100 681 53.6 589 46.4 1270 100 508 56.2 396 43.8 904 100
aParma’s general population as of 31 December 2006 (9).
bPatients registered in the lists of one GP.
cSubjects that completed the questionnaire.
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The diagnosis was based on the ICHD-II criteria.
The questionnaire had already proved valid for the
diagnosis of primary headaches in the same geo-
graphical area (11). The questionnaire versus the
clinical interview had shown an excellent concor-
dance rate (K value of 0.96, 95% CI 0.88 to 1.00);
if more than one headache type were reported, for
the second diagnosis the concordance rate was good
(K value 0.61, 95% CI 0.47 to 0.74). Sensitivity for
migraine without aura, migraine with aura, chronic
migraine, and probable migraine was 100%.
Speciﬁcity was 100%, except for migraine without
aura (93.3%, 95% CI 86 to 100), for typical aura
without migraine and probable migraine (97.8%,
95% CI 94 to 100) (11). The subjects considered
aﬀected by deﬁnite migraine (DM) were those with
a headache that fulﬁlled the ICHD-II criteria for the
diagnosis of migraine without aura (ICHD-II code
1.1), migraine with aura (ICHD-II codes 1.2.1,
1.2.2 and 1.2.3), and chronic migraine (ICHD-II
code 1.5.1). Probable migraine (PM) cases (ICHD-
II codes 1.6.1, 1.6.2 and 1.6.5) were considered both
alone and in combination with DM cases (all
migraine, AM). Subjects with only one headache
attack in the last year were included if they had
had the number of attacks required by their respec-
tive diagnostic criteria in their lifetime.
Sample size
The estimated prevalence of migraine with aura (1) was
assumed as expected prevalence because migraine with
aura has the lowest prevalence in the adult general pop-
ulation among the primary headaches under study. The
accuracy level was between 0.01 and 0.02.
Statistics
Crude prevalence was the number of cases every 100
inhabitants. Crude prevalence was standardised by sex
and age in Parma’s general population aged 18 or over
according to the 2006 census (9). We used the chi-
square test for frequencies diﬀerence and Student’s
t-test for means comparison. The 95% CIs of preva-
lence were calculated assuming that the number of
migraineurs followed a binomial distribution; we used
the method suggested by Schoenberg (12). Statistical
analyses were performed using SPSS version 17.0 for
Windows.
Ethics
The study was approved by the University of Parma
Ethics Board on 13 February 2007. All subjects gave
their informed consent.
Results
Responders and representativeness
The 904 responders (71.2% of the initial study sample)
included 508 women (56.2%; mean age 55.9 years, SD
17.2 years, max. 92 years) and 396 men (43.8%; mean
age 55.0 years, SD 18.2 years, max. 91 years). In 89
cases (48 men and 41 women) the interview was con-
ducted by phone. No statistically signiﬁcant diﬀerences
emerged in gender and age distribution between
Parma’s general population, the initial study sample
and responders. The only exception was the 18–29
years age group, which showed a diﬀerence between
responders and the general population (p¼ 0.046)
(Table 1).
Non-responders
A total of 366 subjects (173 women, 47.3%, and
193 men, 52.7%) could not be recruited to the study
for a variety of reasons (Figure 1). There were signiﬁ-
cantly fewer women than men (p¼ 0.005), especially in
the 40–49 (p¼ 0.002) and 50–59 (p¼ 0.007) age groups.
Mean age was 55.5 years (SD 17.8 years, max. 92 years)
for responders and 51.9 years (SD 17.6 years, max.
89 years) for non-responders (p¼ 0.001).
Crude and adjusted prevalence
Crude prevalence by gender and age for DM, PM and
AM is reported in Table 2. A total of 196 subjects
(21.7%, 95% CI 19.0 to 24.4) had DM, 151 women
(29.7%, 95% CI 25.7 to 33.7) and 45 men (11.4%,
95% CI 8.2 to 14.5). The female-to-male (F :M) ratio
was 2.6 : 1. Age distribution showed a prevalence peak
in the ﬁfth decade, both in women (51.3%, 95% CI 40.2
to 62.4) and in men (21.3%, 95% CI 11.0 to 31.6).
Women showed an additional prevalence peak between
18 and 29 years (51%, 95% CI 37.3 to 64.7; Figure 2A).
281 (22.1%) subjects unreachable (138 F, 143 M) 
28 (2.2%) subjects unable to participate (13 F, 15 M) 
27 (2.1%) subjects unwilling to participate (4 F, 23 M) 
15 (1.2%) subjects dead (10 F, 5 M) 
8 (0.6%) subjects absent (5 F, 3 M) 
7 (0.5%) subjects relocated (3 F, 4 M) 
Initial study sample: 1270 subjects 
Completed the interview: 904 subjects (815 facetoface, 89 by phone)  
Figure 1. Study population flow chart. Eligible sample,
non-participants (with respective reasons), and final sample.
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Thirty-eight subjects (4.2%, 95% CI 2.9 to 5.5) had
PM: 23 (4.5%, 95% CI 2.7 to 6.3) were women and 15
were men (3.8%, 95% CI 1.9 to 5.7) (F :M 1.2 : 1). Men
had a ﬁrst prevalence peak between 18 and 29 years
(9.1%, 95% CI 0.0 to 18.9) and a second, lower peak
in the ﬁfth decade (8.2%, 95% CI 1.3 to 15.1). Women
had one peak in the ﬁfth decade (9.0%, 95% CI 2.6 to
15.3; Figure 2B).
Crude prevalence for AM was 25.9% (95% CI 23.0
to 28.7), 34.3% (95% CI 30.1 to 38.4) in women and
15.2% (95% CI 11.6 to 18.7) in men (F :M 2.3 : 1). Both
men and women showed a prevalence peak in the ﬁfth
decade (29.5%, 95% CI 18.1 to 41.0, and 60.3%, 95%
CI 49.4 to 71.1, respectively). Women also showed a
ﬁrst peak between 18 and 29 years (56.9%, 95% CI
43.3 to 70.5; Figure 2C).
Crude prevalence for each DM subtype is reported
in Table 3. Adjusted prevalence was 24.7% (95% CI
21.9 to 27.5) for DM (13.0%, 95% CI 9.7 to 16.4, in
men and 32.9%, 95% CI 28.8 to 37.0, in women); 5.1%
(95% CI 3.6 to 6.5) for PM (5.2%, 95% CI 3.0 to 7.4, in
men and 5%, 95% CI 3.1 to 6.9, in women); and 29.8%
(95% CI 26.8 to 32.8) for AM (18%, 95% CI 14.3 to
21.8, in men and 37.9%, 95% CI 33.7 to 42.1, in
women).
Discussion
In our study the past-year DM prevalence (29.7% in
women and 11.4% in men) is at the upper limits of the
ranges reported in the literature (1).
The DM gender ratio varies between 1.7 (13) and 3.3
(14) in the European Union, and between 2.2 (15) and
3.1 (16) in North America. Our data (F :M 2.6) agree
with those reported for Western countries.
Table 2. Past-year crude prevalence of migraine by age and gender
Age (years)
M F Total
n % 95% CI n % 95% CI n % 95% CI
Definite migraine (DM)
18–29 3 9.1 0.0–18.9 26 51.0 37.3–64.7 29 34.5 24.4–44.7
30–39 10 19.6 8.7–30.5 23 41.8 28.8–54.9 33 31.1 22.3–39.9
40–49 13 21.3 11.0–31.6 40 51.3 40.2–62.4 53 38.1 30.1–46.2
50–59 7 9.5 2.8–16.1 33 34.4 24.9–43.9 40 23.5 17.2–29.9
60–69 9 10.2 3.9–16.6 21 24.4 15.3–33.5 30 17.2 11.6–22.9
70–79 2 3.1 0.0–7.4 4 4.3 0.2–8.4 6 3.8 0.8–6.8
>79 1 4.0 0.0–11.7 4 8.2 0.5–15.8 5 6.8 1.0–12.5
Total 45 11.4 8.2–14.5 151 29.7 25.7–33.7 196 21.7 19.0–24.4
Probable migraine (PM)
18–29 3 9.1 0.0–18.9 3 5.9 0.0–12.3 6 7.1 1.6–12.7
30–39 4 7.8 0.5–15.2 4 7.3 0.4–14.1 8 7.5 2.5–12.6
40–49 5 8.2 1.3–15.1 7 9.0 2.6–15.3 12 8.6 4.0–13.3
50–59 3 4.1 0.0–8.5 5 5.2 0.8–9.7 8 4.7 1.5–7.9
60–69 – – – 2 2.3 0.0–5.5 2 1.1 0.0–2.7
70–79 – – – 2 2.2 0.0–5.1 2 1.3 0.0–3.0
>79 – – – – – – – – –
Total 15 3.8 1.9–5.7 23 4.5 2.7–6.3 38 4.2 2.9–5.5
All migrainea (AM)
18–29 6 18.2 5.0–31.3 29 56.9 43.3–70.5 35 41.7 31.1–52.2
30–39 14 27.5 15.2–39.7 27 49.1 35.9–62.3 41 38.7 29.4–48.0
40–49 18 29.5 18.1–41.0 47 60.3 49.4–71.1 65 46.8 38.5–55.1
50–59 10 13.5 5.7–21.3 38 39.6 29.8–49.4 48 28.2 21.5–35.0
60–69 9 10.2 3.9–16.6 23 26.7 17.4–36.1 32 18.4 12.6–24.1
70–79 2 3.1 0.0–7.4 6 6.5 1.5–11.4 8 5.1 1.7–8.5
>79 1 4.0 0.0–11.7 4 8.2 0.5–15.8 5 6.8 1.0–12.5
Total 60 15.2 11.6–18.7 174 34. 3 30.1–38.4 234 25.9 23.0–28.7
aAll migraine represents the sum of definite migraine and probable migraine.
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The DM prevalence pick in Western countries is
between 30 and 49 years, for both men and women
(1). Our study showed a comparable pattern: we
found the highest peak between 40 and 49 years in
both genders. The ﬁrst peak between 18 and 29 years
in our female study sample conﬁrmed similar observa-
tions by the authors of the 2001 Swedish study (13) and
of the 2003 British study (17). The decrease in
prevalence after age 50 in both genders was also
observed in other studies published in the literature (1).
In our study population, PM past-year prevalence
was 4.2% (3.8% in men and 4.5% in women) with a
gender ratio of 1.2. In the literature there are few data
about PM. Katsarava et al. reported in the Republic of
Georgia a 9.2% PM prevalence (18), while a recent
Spanish study reported a 4.2% estimate (19), as well
as several studies conducted in the USA (20–22).
Additional data published in 2002 from the American
Migraine Study II (23) indicate a PM prevalence of
2.6% (20), while the American Migraine Prevalence
and Prevention Study reported a 4.5% prevalence
(3.9% in men and 5.1% in women) (22). The US
study, conducted on people involved in a health plan
who had sought medical treatment at least once for any
reason in the preceding 24 months, shows a prevalence
of 14.5% (19.6% in women and 13.1% in men) (21).
Lifetime prevalence of the migrainous disorder coded
to 1.7 in the IHS classiﬁcation is 9.1% in France (24)
and 16.2% in Germany (25).
Chronic migraine (CM) prevalence in our study was
0.2% (95% CI 0.0 to 0.5). A recent systematic review
reports a 0–5.1% global prevalence of CM (26). Of all
the studies considered, only three European studies
deﬁned CM as migraine that occurred on 15 days
per month (or an equivalent yearly rate) according to
IHS criteria (7,26). Prevalence estimates using this
stringent criterion were relatively low and ranged
from 0 to 0.7% (25,27,28).
The high prevalence for DM is the major diﬀerence
between our results and the literature data. Some con-
siderations can be oﬀered. The methodological
approaches to epidemiological studies may determine
a diﬀerence of up to 30% in results (29,30). As regard
the diagnostic criteria, only few authors applied the
ICHD-II (19,21,31–34) as we did in our study, but we
can reasonably exclude that the use of the ICHD-I in
many of previous surveys may have signiﬁcantly biased
results because criteria for the migraine types under
study are basically no diﬀerent.
Table 3. Past-year prevalence of definite migraine subtypes by gender
M F Total
n % 95% CI n % 95% CI n % 95% CI
MOa 35 8.8 6.0–11.6 133 26.2 22.4–30.0 168 18.6 16.0–21.1
MAa 13 3.3 1.5–0.05 27 5.3 3.4–7.3 40 4.4 3.1–5.8
CM – – – 2 0.4 0.2–0.9 2 0.2 0–0.5
MO: migraine without aura; MA: migraine with aura; CM: chronic migraine.
aIn 14 cases (3 men and 11 women), patients had a diagnosis of migraine with and without aura.
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Figure 2. Past-year crude prevalence of definite migraine
(A), probable migraine (B), and all migraine types (C) by age and
gender.
*1¼ 18–29; 2¼ 30–39; 3¼ 40–49; 4¼ 50–59; 5¼ 60–69;
6¼ 70–79; 7 80 years.
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The published migraine prevalence studies appear
also to diﬀer with respect to the age groups considered.
Some studies deﬁne a minimum inclusion age of 12
(16,23,33), 13 (34), 15 (35) and 16 years (17,18,32),
i.e. the prevalence estimate is also based on data from
adolescents. Similarly, other studies don’t consider
elderly patients (14,17,36–38), such as the 2004 US
study, which was conducted on people aged up to 55
years (21). Finally, there are countless other studies that
estimate prevalence only in limited age groups (1). Our
study population was an adult population aged 18
years or over, with no upper age limits and advanced
mean age (around 55 years). However, if we consider
that migraine prevalence tends to decrease progres-
sively in old age, not even the age factor can explain
our high DM prevalence.
Another, and probably more important, methodo-
logical diﬀerence concerns the procedures followed for
the interview. A primary headache diagnosis is based
on oﬃcially recognised and well-established diagnostic
criteria. From the practical point of view, it must rely
on an in-depth discussion with the patient to compen-
sate for the absence of any laboratory or instrumental
markers. In epidemiological studies, the interviewer
and the interview mode that ideally reproduce the
best investigational ‘clinical setting’ are represented by
a physician experienced in headache disorders perform-
ing a face-to-face interview and a neurological exami-
nation as we did. This is undoubtedly a procedure that
carries the disadvantage of being very time-consuming
and requiring highly specialised personnel. As a result,
it is hardly applicable in very large populations.
The Danish study (36) was performed by a face-to-
face interview and the authors reported a lower DM
prevalence (10%) than ours. However, only one study
doesn’t allow a conclusive evaluation. Other interview
modes, less accurate but more suitable to investigating
large patient samples, are the structured self-adminis-
tered questionnaire (14,16,23,33,34,39,40), the personal
interview conducted by trained non-medical personnel
(15,31) and, especially in Anglo-Saxon countries,
computer-assisted telephone interviewing (CATI)
(17,19,21,37,38).
We know that often interviewees will not answer in
such an unequivocal way as the diagnostic criteria of
international classiﬁcations would require them to.
Instead, they tend to use adverbs or circumlocutions
that render their answers ambiguous. The interviewers
may diﬀer widely, depending on whether he/she is a
headache specialist or a lay interviewer: the former
will try to clarify the answer by asking more questions
based on his/her clinical skills; by contrast the latter,
unable to use clinical reasoning, will be forced to trans-
late the interviewee’s vague answer into a kind of
answer that is accurate but obviously arbitrary.
Eventually, the medical expert and the lay interviewer
may interpret the interviewee’s answer in an entirely
opposite way and their diagnoses will be completely
diﬀerent.
Having the interview conducted by physicians with
proven experience in headache disorders enabled us
ﬁrst to perform a ‘generic’ screening of headache
patients (‘Have you had a headache in the last year?’)
and then to establish a possible diagnosis of migraine
thanks to the accurate evaluation of all headache clin-
ical features detected by the questionnaire.
This procedure also avoided a screening method
based on such headache features as severity, frequency,
the use of anti-migraine drugs, etc. A criterion often
used to screen migraine is headache severity. While
that criterion is helpful when investigators evaluate
the social burden of migraine, it can easily lead to prev-
alence underestimation. It is in fact possible to make
a migraine diagnosis that entirely fulﬁls the ICHD-II
criteria even when the headache occurs with a less
than ‘strong’ severity. Diﬀerent epidemiological
studies in the USA and Europe have used headache
severity as a screening criterion for migraine
(15,16,21,23,31,37,38). The detected cases were then
investigated further in order to establish a diagnosis
and migraine prevalence was estimated at 8.5% (15)
to 14.7% (21).
A further explanation for the high DM prevalence
found in our study might be that we also identiﬁed as
DM cases those subjects who had had only one attack
in the year preceding the study, and we judged that the
A criterion (‘at least ﬁve attacks fulﬁlling criteria B–D’)
set by the ICHD-II for migraine without aura diagnosis
had been fulﬁlled even though four of the ﬁve attacks
had occurred before the study year. Instead, if we had
considered the A criterion fulﬁlled only in those sub-
jects with at least ﬁve attacks in the year preceding the
study, clearly past-year prevalence would have been
lower than we reported. Unfortunately, the other epi-
demiological studies in the literature do not provide any
clear indications in this respect and so we cannot deter-
mine how and to what extent our choice may have
aﬀected disparities between data. We expect to ﬁnd
some explanation through a future distribution analysis
of our DM patients based on frequency of attacks and
number of days of headache.
These two parameters are of great importance not
only for systematic description and classiﬁcation pur-
poses (41), but also for epidemiological studies, as was
indirectly conﬁrmed by Katsarava et al. (42), which
reported data from the population-based survey of
the German Headache Consortium. This survey was
conducted on 9350 subjects aged 18–65 years through
a validated questionnaire. The prevalence of high-
frequency episodic migraine (9–14 days of migraine
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per month) – which was present in 228 subjects – and of
low-frequency episodic migraine (8 days of migraine
per month) – which occurred in as many as 2356 sub-
jects, was 27.6%, higher than the one found in our
study.
In conclusion, our study results indicate a migraine
prevalence at the upper limits of the data ranges cur-
rently available for the European Union and North
America. It is likely that diﬀerent methodological
approaches led to data disparities between the diﬀerent
studies published in the literature. However, an actual
higher frequency of migraine in the Italian general
population cannot be excluded.
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